Organon Total Other Income Expense Net Over Time
OGN Stock | USD 15.36 0.30 1.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Organon Performance and Organon Correlation. Organon |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Other Income Expense Net Analysis
Compare Organon and related stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Amicus Therapeutics Total Other Income Expense Net Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRNX | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (48 K) | 1.6 M | 3.4 M | 1.1 M | 61 K | 4 M | 8.1 M | 8.5 M |
ENTA | 791 K | (8 K) | 598 K | 283 K | 1.3 M | 1.7 M | 2.3 M | 4.8 M | 8.8 M | 6.6 M | 2 M | 1.7 M | 6.2 M | 3.9 M | 3.1 M |
FOLD | (168 K) | 2.8 M | 674 K | (1.1 M) | (114 K) | (5.4 M) | (24.9 M) | (225.1 M) | (11.7 M) | (55.2 M) | (30.4 M) | (41.6 M) | (37.6 M) | (76.6 M) | (72.8 M) |
CNTB | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (58.4 M) | (89.1 M) | (103.2 M) | (403.7 K) | 2.7 M | 2.8 M |
LGND | (5.5 M) | (50 K) | (4.8 M) | (6.8 M) | (9.4 M) | 7 M | (37 M) | (10.8 M) | 43.9 M | 802.4 M | (36.4 M) | (31.6 M) | 33 M | 51.7 M | 54.3 M |
PASG | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (8.4 M) | 670 K | 343 K | 2.3 M | 6.3 M | 6.6 M |
ORIC | 233 K | 233 K | 233 K | 233 K | 233 K | 233 K | 233 K | 233 K | 233 K | 1.7 M | 483 K | 156 K | 2.6 M | 10.1 M | 10.6 M |
LYEL | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | (27.3 M) | 7.5 M | (36.7 M) | 3.8 M | 12.4 M | 13 M |
DSGN | (139 K) | (139 K) | (139 K) | (139 K) | (139 K) | (139 K) | (139 K) | (139 K) | (139 K) | (139 K) | 50 K | 298 K | 4.3 M | 11.3 M | 11.9 M |
RVMD | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | 2 K | (2.1 M) | 2.1 M | 2.2 M | 917 K | 9.2 M | 47.3 M | 49.7 M |
Organon and related stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Amicus Therapeutics Total Other Income Expense Net description
My Equities
My Current Equities and Potential Positions
Organon Co | OGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | New Jersey; U.S.A |
Exchange | New York Stock Exchange |
USD 15.36
Check out Organon Performance and Organon Correlation. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Organon technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.